Barclays Downgrades PolyPeptide Amid Samsung Biologics Takeover Bid

By EC Assets · Published 14 August 2026

Barclays has downgraded PolyPeptide Group. The downgrade follows a strong first half rally for PolyPeptide. A public tender offer from Samsung Biologics has also occurred. Samsung Biologics, based in South Korea, made an all, cash bid for Switzerland's PolyPeptide Group. The offer totaled 1.46 billion Swiss francs, equivalent to $1.8 billion. Samsung Biologics announced its intention to launch an all, cash public tender offer for 100% of PolyPeptide's fully diluted share capital. This excludes any treasury shares. The proposed offer price is CHF 44.31 per share. Samsung Biologics aims to acquire PolyPeptide Group through this all, cash deal, valued at SFr1.46 billion or $1.81 billion. This acquisition is part of Samsung Biologics' strategy to accelerate its multi, modality approach. It also aims to expand its global network across the U.S. Europe, and India. The downgrade from Barclays comes after a period of strong performance for PolyPeptide in the first half of the year. This event follows the public offer from Samsung Biologics. The offer details a specific share price for the acquisition. Investors will observe further developments regarding the tender offer process. The market will also monitor PolyPeptide's performance following the downgrade and the proposed acquisition. This article is intended for informational purposes only. It does not constitute investment advice.